Wedbush Downgrades Amicus Therapeutics (FOLD) to Underperform, Sees Another 50% Slide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Cuts PT on Amicus Therapeutics (FOLD), But Remains Overall Bullilsh
December 20, 2012 12:25 PM ESTLeerink Swann cut its price target on Amicus Therapeutics (NASDAQ: FOLD) from $9 to $5 after the company reported Wednesday that Phase III study ('011) of Amigal monotherapy in Fabry disease missed its primary and secondary endpoints. However, they maintained an Outperform rating.... More
Amicus Therapeutics (FOLD), Glaxo (GSK) Report Study 011 Did Not Achieve Primary Endpoint
December 19, 2012 4:12 PM ESTAmicus Therapeutics (Nasdaq: FOLD) and GlaxoSmithKline plc (NYSE: GSK) announced the 6-month primary treatment period results from the first Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay. Study 011 randomized a total of 67 patients to receive oral migalastat HCl 150 mg or placebo on an every-other-day (QOD) dosing schedule during a 6-month, double-blind primary treatment period.
Reduction of GL-3 Substrate in Kidney Interstitial Capillaries:
... More
